Sustained expression of vascular endothelial growth factor and angiopoietin-1 improves blood-spinal cord barrier integrity and functional recovery after spinal cord injury.
Spinal cord injury (SCI) results in immediate disruption of the spinal vascular network, triggering an ischemic environment and initiating secondary degeneration. Promoting angiogenesis and vascular stability through the induction of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), respectively, provides a possible therapeutic approach in treating SCI. We examined whether supplementing the injured environment with these two factors, which are significantly reduced following injury, has an effect on lesion size and functional outcome. Sustained delivery of both VEGF(165) and Ang-1 was realized using viral vectors based on the adeno-associated virus (AAV), which were injected directly into the lesion epicenter immediately after injury. Our results indicate that the combined treatment with VEGF and Ang-1 resulted in both reduced hyperintense lesion volume and vascular stabilization, as determined by magnetic resonance imaging (MRI). Western blot analysis indicated that the viral vector expression was maintained into the chronic phase of injury, and that the use of the AAV vectors did not exacerbate infiltration of microglia into the lesion epicenter. The combined treatment with AAV-VEGF and AAV-Ang-1 improved locomotor recovery in the chronic phase of injury. These results indicate that combining angiogenesis with vascular stabilization may have potential therapeutic applications following SCI.
Herrera
Juan J
JJ
Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA. Juan.Herrera@uth.tmc.edu
Sundberg
Laura M
LM
Zentilin
Lorena
L
Giacca
Mauro
M
Narayana
Ponnada A
PA
D042683:Angiopoietin-1 / Q000096:biosynthesis* / Q000235:genetics*; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D015153:Blotting, Western; D000229:Dependovirus / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D006614:Hindlimb / Q000502:physiology; D007150:Immunohistochemistry; D008124:Locomotion / Q000502:physiology; D008279:Magnetic Resonance Imaging; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000502:physiology; D010539:Permeability; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000502:physiology*; D013119:Spinal Cord Injuries / Q000473:pathology* / Q000628:therapy*; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics*
D042683:Angiopoietin-1; D042461:Vascular Endothelial Growth Factor A
Neuroscience. 2003;120(4):951-60
12927201
J Neuropathol Exp Neurol. 1983 Nov;42(6):707-19
6631457
Mol Neurobiol. 2001 Apr-Jun;23(2-3):121-35
11817215
Magn Reson Med. 2001 Apr;45(4):614-22
11283989
Exp Neurol. 2004 Jun;187(2):388-402
15144865
Spinal Cord. 2003 Jul;41(7):369-78
12815368
Acta Pharmacol Sin. 2007 Apr;28(4):493-502
17376288
Nat Med. 2003 Jun;9(6):669-76
12778165
J Cereb Blood Flow Metab. 2005 Sep;25(9):1111-8
15829918
J Neurotrauma. 2001 Oct;18(10):1091-105
11686495
Cell. 1996 Dec 27;87(7):1161-9
8980223
Hum Gene Ther. 1997 Nov 1;8(16):1891-900
9382955
Nat Med. 1997 Mar;3(3):306-12
9055858
Microcirculation. 2006 Sep;13(6):423-37
16864410
Circulation. 1999 Jan 19;99(2):201-5
9892583
J Clin Invest. 2003 Jun;111(12):1843-51
12813020
J Neurotrauma. 2009 Jul;26(7):995-1003
19257807
FASEB J. 1999 Jan;13(1):9-22
9872925
Electroencephalogr Clin Neurophysiol. 1989 Jul-Aug;74(4):241-59
2471626
Magn Reson Imaging. 1998 Dec;16(10):1249-55
9858282
J Immunol. 2010 Jan 15;184(2):1031-40
20008293
J Neurochem. 2004 Apr;89(2):503-13
15056293
Prog Neurobiol. 1998 Jul;55(4):399-432
9654386
Spine (Phila Pa 1976). 1990 Jul;15(7):630-8
2218708
Stroke. 2000 Jan;31(1):208-13
10625739
Cell. 1996 Dec 27;87(7):1171-80
8980224
J Neurosurg. 1977 Oct;47(4):577-81
903810
Neurochirurgie. 1991;37(5):291-302
1758561
J Cereb Blood Flow Metab. 1998 Aug;18(8):887-95
9701350
Neurosurgery. 1990 Jun;26(6):952-7
2362673
Exp Neurol. 1987 Mar;95(3):548-70
3817079
Nat Med. 2000 Apr;6(4):460-3
10742156
J Neurotrauma. 2009 Jul;26(7):1005-16
19226205
Mol Ther. 2003 Apr;7(4):450-9
12727107
J Cereb Blood Flow Metab. 2000 Feb;20(2):387-95
10698077
J Neurotrauma. 2000 Mar;17(3):219-29
10757327
J Neurotrauma. 2003 Feb;20(2):179-93
12675971
Clin Sci (Lond). 2008 Jun;114(12):707-18
18078386
Acta Neurochir (Wien). 2003 Jan;145(1):49-53
12545262
Exp Neurol. 1998 May;151(1):77-88
9582256
Brain. 2010 Apr;133(Pt 4):1026-42
20375135
J Cereb Blood Flow Metab. 2002 Apr;22(4):379-92
11919509
J Neurotrauma. 1995 Feb;12(1):1-21
7783230
Ann Neurol. 2006 May;59(5):843-51
16634039
Trends Pharmacol Sci. 2003 Jan;24(1):13-7
12498725
J Neuropathol Exp Neurol. 2002 Oct;61(10):914-25
12387457
Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2619-26
17901375
Neuroscience. 2002;113(3):683-7
12150788
J Neurosurg. 1991 Jul;75(1):15-26
2045903
J Neurotrauma. 2002 Oct;19(10):1251-60
12427332
Hum Gene Ther. 2007 Jun;18(6):515-24
17559317
Nature. 2005 Dec 15;438(7070):954-9
16355213
Neurol Res. 2010 Sep;32(7):748-55
19660197
Neurobiol Dis. 2010 Feb;37(2):384-93
19879362
Science. 1999 Dec 24;286(5449):2511-4
10617467
Eur J Pharmacol. 2007 Jul 30;568(1-3):222-30
17553485
Int J Mol Med. 2009 Feb;23(2):279-84
19148554
J Neurosci Res. 2006 Apr;83(5):801-10
16456864
Eur J Neurosci. 1999 Oct;11(10):3648-58
10564372
Lab Invest. 2003 Aug;83(8):1211-22
12920250
NMR Biomed. 2009 Apr;22(3):332-41
19023867
J Magn Reson Imaging. 1999 Sep;10(3):223-32
10508281